Skip to Content

Ninlaro Side Effects

Generic Name: ixazomib

Note: This document contains side effect information about ixazomib. Some of the dosage forms listed on this page may not apply to the brand name Ninlaro.

In Summary

Common side effects of Ninlaro include: constipation, diarrhea, macular eruption, maculopapular rash, nausea, peripheral edema, peripheral neuropathy, peripheral sensory neuropathy, skin rash, and vomiting. Other side effects include: hepatic insufficiency. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to ixazomib: oral capsule

Along with its needed effects, ixazomib (the active ingredient contained in Ninlaro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ixazomib:

More Common

  • Abdominal or stomach pain
  • black, tarry stools
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • chills
  • cough
  • dark urine
  • diarrhea
  • dizziness
  • fever
  • headache
  • itching or rash
  • light-colored stools
  • loss of appetite
  • lower back or side pain
  • nausea
  • numbness, tingling, or pain in the hands or feet
  • painful or difficult urination
  • pale skin
  • rapid weight gain
  • rash with flat lesions or small raised lesions on the skin
  • redness or discoloration of the skin
  • sore throat
  • tingling of the hands or feet
  • ulcers, sores, or white spots in the mouth
  • unpleasant breath odor
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • vomiting of blood
  • yellow eyes or skin

Less Common

  • Bleeding gums
  • blood in the urine or stools


  • Blistering, peeling, or loosening of the skin
  • bloody nose
  • heavier menstrual periods
  • joint or muscle pain
  • red skin lesions, often with a purple center
  • red, irritated eyes

Some side effects of ixazomib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Back pain
  • blurred vision
  • body aches or pain
  • burning, dry, or itching eyes
  • difficulty having a bowel movement (stool)
  • discharge, excessive tearing
  • ear congestion
  • loss of voice
  • nasal congestion
  • redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
  • sneezing

For Healthcare Professionals

Applies to ixazomib: oral capsule


Very common (10% or more): Peripheral edema (18%)[Ref]


Very common (10% or more): Rash (11%)

Postmarketing reports: Acute febrile neutrophilic dermatosis (Sweet's syndrome), Stevens-Johnson syndrome[Ref]


Very common (10% or more): Diarrhea (36%), constipation (25%), nausea (21%)[Ref]


Very common (10% or more): Thrombocytopenia (78%), neutropenia (67%), thrombotic thrombocytopenic purpura[Ref]


Frequency not reported: Hepatotoxicity[Ref]


Postmarketing reports: Transverse myelitis[Ref]


Postmarketing reports: Tumor lysis syndrome[Ref]


Very common (10% or more): Back pain (16%)[Ref]

Nervous system

Frequency not reported: Peripheral neuropathy (21%)

Postmarketing reports: Posterior reversible encephalopathy syndrome[Ref]


Common (1% to 10%): Blurred vision, dry eye, conjunctivitis[Ref]


Very common (10% or more): Upper respiratory tract infection (14%)[Ref]


1. "Product Information. Ninlaro (ixazomib)." Takeda Pharmaceuticals America, Lincolnshire, IL.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Related questions